News

First drug to treat bronchiectasis lung condition approved by FDA

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...
Pharmaceutical Technology on MSN2d

Insmed wins FDA approval for future blockbuster Brinsupri

Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...
Medical Dialogues16h

FDA Approves Brensocatib as First Treatment for Non-Cystic Fibrosis Bronchiectasis

The FDA has approved oral brensocatib (Brinsupri) for adults and children 12+ with non-cystic fibrosis bronchiectasis. As a ...
pharmaphorum2d

Insmed gets first FDA approval for bronchiectasis

Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease ...
The American Journal of Managed Care3d

Brensocatib Becomes First FDA-Approved Therapy for Bronchiectasis

Brensocatib (Brinsupri; Insmed) gains FDA approval as the first treatment for bronchiectasis, offering hope to patients with ...
BioSpace2d

Insmed Wins Approval for First Bronchiectasis Drug and DPP1 Blocker

Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...
Fierce Pharma3d

Insmed’s Brinsupri scores landmark FDA nod in bronchiectasis, marking first approval of a DPP1 inhibitor

With a landmark U.S. approval  Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. | The FDA on Tuesday signed ...
STAT3d

Insmed’s lung disease drug approved in the U.S.

Insmed has received FDA clearance for the first treatment for a chronic lung disease, opening the biotech up to what could be ...

PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...
BioPharma Dive3d

Insmed gains US approval of lung disease drug forecast to be blockbuster

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...
PharmExec3d

FDA Approves Insmed’s Brinsupri as First Treatment for Non-Cystic Fibrosis Bronchiectasis

Brinsupri is a first-in-class DPP1 inhibitor that has been found to inhibit activation of neutrophil enzymes that drive chronic airway inflammation in non-cystic fibrosis bronchiectasis.